The Lancet Oncology on X: NEW: phase 2 GORTEC 2014-01 TPExtreme trial: TPEx (cetuximab+docetaxel+cisplatin) vs EXTREME (platinum+fluorouracil+cetuximab) in recurrent or metastatic head and neck squamous-cell carcinoma #headandneckcancer
Par un écrivain mystérieux
Description
Cisplatin, Fluorouracil, and Docetaxel in Unresectable Head and
A randomized phase III study of fractionated docetaxel
Avelumab as neoadjuvant therapy in patients with urothelial non
Frontiers A Multicenter Phase II Trial of Docetaxel, Cisplatin
Rituximab in combination with gemcitabine plus cisplatin in
Frontiers Feasibility of Induction Docetaxel, Cisplatin, 5
Pembrolizumab vs the EXTREME Regimen in Recurrent or Metastatic
Perioperative dose-dense methotrexate, vinblastine, doxorubicin
Cetuximab, fluorouracil and cisplatin with or without docetaxel
Frontiers A Multicenter Phase II Trial of Docetaxel, Cisplatin
Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and
Progress in systemic therapy for advanced-stage urothelial
Frontiers A Multicenter Phase II Trial of Docetaxel, Cisplatin
Changes in neutrophile-to-lymphocyte ratio as predictive and
depuis
par adulte (le prix varie selon la taille du groupe)